|
WO2020181163A1
|
|
Lipid-based formulation of cenicriviroc
|
|
CN110167550A
|
|
The solid form and preparation method thereof of Xi Keliweiluo mesylate
|
|
MX2018015871A
|
|
Purified cenicriviroc and purified intermediates for making cenicriviroc.
|
|
KR20180088373A
|
|
Synergistic combination therapy for the treatment of fibrosis
|
|
WO2016123541A2
|
|
Cenicriviroc for the treatment of encephalitis infection
|
|
AU2015371250A1
|
|
Process of making cenicriviroc and related analogs
|
|
SG11201706028RA
|
|
Cenicriviroc for the treatment of fibrosis
|
|
SG10201902137PA
|
|
Cenicriviroc combination therapy for the treatment of fibrosis
|
|
WO2015187663A1
|
|
Cenicriviroc for the treatment of hiv-2 infection
|
|
KR20160132489A
|
|
Cenicriviroc for the treatment of fibrosis
|
|
US2016081985A1
|
|
Cenicriviroc compositions and methods of making and using the same
|
|
US2015368232A1
|
|
Lamivudine salts
|
|
AU2013355043A1
|
|
Oligonucleotide formulation
|
|
AU2011315903A1
|
|
Nucleic acid modulators of CLEC-2
|
|
AU2010256511A1
|
|
Nucleic acid modulators of glycoprotein VI
|
|
EP1423376A1
|
|
Bicyclic compound, production and use thereof
|
